eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
3/2009
vol. 13
 
Share:
Share:
more
 
 
abstract:
Review paper

Sequential therapy in treatment of patients with metastatic renal cell carcinoma

Jakub Żołnierek

Współczesna Onkologia (2009) vol. 13; 3 (113-119)
Online publish date: 2009/07/23
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
As metastatic renal cell carcinoma (mRCC) is particularly resistant to available treatment modalities there is a strong need for development of new strategies to be used in therapy of patients with such diagnosis. Immunotherapy – in Poland typically based on subcutaneous injections of interferon a – although having the ability to eradicate tumour does so only in a small percentage of patients. Because of its relatively low efficacy the indications for use of immunotherapy are restricted. Thanks to the introduction of novel drugs into clinical practice – tyrosine and serine-threonine kinase inhibitors and monoclonal antibodies – objective responses are seen more often. Despite their significant influence on progression-free survival, the impact on overall survival is not so clear and complete remissions are casuistic. Pharmacotherapy of metastatic renal cell cancer is still the palliative treatment, aimed at decelerating tumour growth and delaying the moment it reaches its critical burden. For this reason it is crucial to look for new strategies of care. One of them is sequential therapy – an attractive option available now and with predictive and tolerant toxicity. The paper provides a short discussion of the problem.
keywords:

metastatic renal cell cancer, targeted therapy, tyrosine and serine-threonine kinase inhibitors, monoclonal antibodies, sequential therapy

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe